Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
5
×
boston
boston blog main
boston top stories
life sciences
national blog main
5
×
clinical trials
drugs
fda
patisiran
rna interference
akcea therapeutics
hereditary transthyretin amyloidosis
inotersen
national top stories
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
tafamidis
aminolevulinic acid
givosiran
pfizer
san francisco blog main
san francisco top stories
vyndaqel
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
andrew fire
barry greene
biotech
boston university
craig mello
dan ollendorf
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
What
alnylam
medicine
5
×
drug
fda
rna
rnai
interference
pharmaceuticals
ago
ok
second
seek
speedy
uses
afternoon
alnylam’s
approval
approve
approved
approves
awaits
biological
cells
cleared
crossed
data
decades
decision
discovered
ema
employ
europe
far
fingers
follows
friday
gene
gets
harmful
historic
Language
Current search:
" national blog main "
×
medicine
×
" alnylam pharmaceuticals "
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision